Esmo2020: Metastasierter Triple Negativer Brustkrebs: Ascent-Studie Mit Sacituzumab Govitecan

ESMO2020: Metastasierter triple negativer Brustkrebs: ASCENT-Studie mit Sacituzumab govitecan (SG)

ESMO 2020: Meta. triple negativer Brustkrebs (TNBC): ASCENT-Studie mit Sacituzumab govitecan (SG)

Brustkrebs Deutschland e.V.

ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC

The ASCENT of sacituzumab govitecan in metastatic TNBC | Aditya Bardia

Medicine Matters oncology

SABCS 2020: Triple neg., metastasierter Brustkrebs: Neue Therapieoption mit Sacituzumab Govitecan.

Brustkrebs Deutschland e.V.

ASCENT trial: sacituzumab govitecan for TNBC

Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer

Oncotarget: Sacituzumab Govitecan in Triple-Negative Breast Cancer

Sacituzumab Govitecan in mTNBC

Breast cancer at ESMO 2020: IMpassion131, SOLAR-1, PALLAS and more

Breast cancer trials of interest at ESMO 2022

Combination Immunotherapy Appears Promising in Breast Cancer Subtypes

Targeted Oncology

ESMO 2020: Triple neg. Brustkrebs (TNBC): Neoadjuvant Atezolizumab + Chemotherapie (IMpassion031)

Brustkrebs Deutschland e.V.

Sacituzumab govitecan for treatment-refractory metastatic breast cancer

BEAT-SC: Phase III trial of bevacizumab or placebo with atezolizumab & chemo in extensive-stage SCLC

Updates in metastatic triple-negative breast cancer at ESMO 2023

KEYNOTE-355: pembro + chemo in triple-negative breast cancer

Dr. Cynthia Ma on the METRIC Trial in Triple-Negative Breast Cancer

PALOMA-3: Phase 3 trial of fulvestrant with palbociclib for metastatic breast cancer

EMJ

Review of Recent Progress in Immunotherapy in Triple Negative Breast Cancer Schmid 1

GRACE - Global Resource for Advancing Cancer Education